EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104

BACKGROUND: We aimed to identify molecular epidermal growth factor receptor (EGFR) tissue biomarkers in pancreatic cancer (PC) patients treated with the anti-EGFR agent erlotinib within the phase 3 randomised AIO-PK0104 study. METHODS: AIO-PK0104 was a multicenter trial comparing gemcitabine/erlotin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Boeck, S, Jung, A, Laubender, R P, Neumann, J, Egg, R, Goritschan, C, Vehling-Kaiser, U, Winkelmann, C, Fischer von Weikersthal, L, Clemens, M R, Gauler, T C, Märten, A, Klein, S, Kojouharoff, G, Barner, M, Geissler, M, Greten, T F, Mansmann, U, Kirchner, T, Heinemann, V
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2013
Assuntos:
Genetics & Genomics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3566829/
https://ncbi.nlm.nih.gov/pubmed/23169292
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.495
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados